Literature DB >> 8586109

Reduced GABAA receptor density contralateral to a potentially epileptogenic MRI abnormality in a patient with complex partial seizures.

T Kuwert1, S R Stodieck, C Puskás, B Diehl, Z Puskaś, G Schuierer, B Vollet, O Schober.   

Abstract

Imaging cerebral GABAA receptor density (GRD) with single-photon emission tomography (SPET) and iodine-123 iomazenil is highly accurate in lateralizing epileptogenic foci in patients with complex partial seizures of temporal origin. Limited knowledge exists on how iomazenil SPET compares with magnetic resonance imaging (MRI) in this regard. We present a patient with complex partial seizures in whom MRI had identified an arachnoid cyst anterior to the tip of the left temporal lobe. Contralaterally to this structural abnormality, interictal electroencephalography (EEG) performed after sleep deprivation disclosed an intermittent frontotemporal dysrhythmic focus with slow and sharp waves. On iomazenil SPET images GRD was significantly reduced in the right temporal lobe and thus contralaterally to the MRI abnormality, but ipsilaterally to the pathological EEG findings. These data suggest that iomazenil SPET may significantly contribute to the presurgical evaluation of epileptic patients even when MRI identifies potentially epileptogenic structural lesions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8586109     DOI: 10.1007/bf01736996

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  12 in total

1.  THE TEMPORAL LOBE AGENESIS SYNDROME.

Authors:  R G ROBINSON
Journal:  Brain       Date:  1964-03       Impact factor: 13.501

2.  The anterior temporal electrode and the ten-twenty system.

Authors:  D SILVERMAN
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1960-08

3.  In-vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci.

Authors:  I Savic; A Persson; P Roland; S Pauli; G Sedvall; L Widén
Journal:  Lancet       Date:  1988-10-15       Impact factor: 79.321

4.  Arachnoid cysts of the middle cranial fossa: a clinical, radiological and follow-up study.

Authors:  S Passero; G Filosomi; R Cioni; C Venturi; B Volpini
Journal:  Acta Neurol Scand       Date:  1990-08       Impact factor: 3.209

5.  Presurgical evaluation for partial epilepsy: relative contributions of chronic depth-electrode recordings versus FDG-PET and scalp-sphenoidal ictal EEG.

Authors:  J Engel; T R Henry; M W Risinger; J C Mazziotta; W W Sutherling; M F Levesque; M E Phelps
Journal:  Neurology       Date:  1990-11       Impact factor: 9.910

Review 6.  The relative contributions of MRI, SPECT, and PET imaging in epilepsy.

Authors:  S S Spencer
Journal:  Epilepsia       Date:  1994       Impact factor: 5.864

7.  Physical performance of the Siemens MultiSPECT 3 gamma camera.

Authors:  J T Kuikka; M Tenhunen-Eskelinen; J Jurvelin; H Kiiliänen
Journal:  Nucl Med Commun       Date:  1993-06       Impact factor: 1.690

8.  Evaluation of a multicentre study with Iomazenil--a benzodiazepine receptor ligand.

Authors:  P A Schubiger; P H Hasler; H Beer-Wohlfahrt; A Bekier; R Oettli; M Cordes; F Ferstl; E Deisenhammer; M De Roo; E Moser
Journal:  Nucl Med Commun       Date:  1991-07       Impact factor: 1.690

9.  Diagnosis and treatment of middle fossa arachnoid cysts and subdural hematomas.

Authors:  L M Auer; B Gallhofer; G Ladurner; W D Sager; F Heppner; H Lechner
Journal:  J Neurosurg       Date:  1981-03       Impact factor: 5.115

10.  Evaluation of focal epilepsy: a SPECT scanning comparison of 123-I-iomazenil versus HM-PAO.

Authors:  M Cordes; H Henkes; F Ferstl; B Schmitz; J Hierholzer; D Schmidt; R Felix
Journal:  AJNR Am J Neuroradiol       Date:  1992 Jan-Feb       Impact factor: 3.825

View more
  1 in total

1.  Functional assessment of intracranial arachnoid cysts with TC99 m-HMPAO SPECT: a preliminary report.

Authors:  Juan F Martínez-Lage; José A Valentí; Claudio Piqueras; Antonio M Ruiz-Espejo; Francisco Román; Juan A Nuño de la Rosa
Journal:  Childs Nerv Syst       Date:  2006-02-22       Impact factor: 1.475

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.